Q4 2024 Earnings Estimate for Gilead Sciences, Inc. (NASDAQ:GILD) Issued By Zacks Research

Gilead Sciences, Inc. (NASDAQ:GILD) – Research analysts at Zacks Research dropped their Q4 2024 earnings estimates for shares of Gilead Sciences in a research report issued on Monday, October 7th. Zacks Research analyst E. Bagri now anticipates that the biopharmaceutical company will post earnings of $1.45 per share for the quarter, down from their previous estimate of $1.47. The consensus estimate for Gilead Sciences’ current full-year earnings is $3.78 per share. Zacks Research also issued estimates for Gilead Sciences’ Q2 2025 earnings at $1.70 EPS and FY2025 earnings at $7.12 EPS.

Several other equities research analysts have also weighed in on the stock. Evercore ISI upgraded shares of Gilead Sciences to a “strong-buy” rating in a research note on Friday, August 9th. Barclays increased their price objective on shares of Gilead Sciences from $76.00 to $84.00 and gave the stock an “equal weight” rating in a research note on Monday. Royal Bank of Canada increased their price objective on shares of Gilead Sciences from $74.00 to $75.00 and gave the stock a “sector perform” rating in a research note on Friday, October 4th. Piper Sandler reiterated an “overweight” rating and set a $95.00 price objective on shares of Gilead Sciences in a research note on Wednesday, September 11th. Finally, Truist Financial increased their price objective on shares of Gilead Sciences from $82.00 to $83.00 and gave the stock a “hold” rating in a research note on Thursday, August 15th. Eleven equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $83.94.

Gilead Sciences Price Performance

GILD opened at $85.21 on Wednesday. The firm has a market cap of $106.16 billion, a price-to-earnings ratio of 236.69, a price-to-earnings-growth ratio of 2.91 and a beta of 0.18. Gilead Sciences has a fifty-two week low of $62.07 and a fifty-two week high of $87.86. The company’s 50-day moving average price is $79.20 and its 200 day moving average price is $71.98. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.40. The company had revenue of $6.95 billion during the quarter, compared to the consensus estimate of $6.64 billion. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%.

Institutional Trading of Gilead Sciences

A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in Gilead Sciences by 2.6% during the first quarter. Vanguard Group Inc. now owns 114,732,575 shares of the biopharmaceutical company’s stock worth $8,404,161,000 after buying an additional 2,910,147 shares in the last quarter. Capital World Investors boosted its stake in Gilead Sciences by 1.4% in the 1st quarter. Capital World Investors now owns 84,497,404 shares of the biopharmaceutical company’s stock worth $6,189,435,000 after purchasing an additional 1,133,281 shares during the period. Capital Research Global Investors boosted its stake in Gilead Sciences by 2.7% in the 1st quarter. Capital Research Global Investors now owns 61,246,366 shares of the biopharmaceutical company’s stock worth $4,486,296,000 after purchasing an additional 1,589,240 shares during the period. Wellington Management Group LLP boosted its stake in Gilead Sciences by 14.4% in the 4th quarter. Wellington Management Group LLP now owns 18,630,134 shares of the biopharmaceutical company’s stock worth $1,509,227,000 after purchasing an additional 2,350,550 shares during the period. Finally, Legal & General Group Plc boosted its stake in Gilead Sciences by 0.8% in the 2nd quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock worth $851,743,000 after purchasing an additional 93,068 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Insider Activity

In other news, insider Johanna Mercier sold 29,357 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the transaction, the insider now directly owns 78,127 shares in the company, valued at $6,545,480.06. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, insider Johanna Mercier sold 29,357 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the sale, the insider now directly owns 78,127 shares in the company, valued at approximately $6,545,480.06. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the sale, the insider now owns 100,189 shares of the company’s stock, valued at $8,398,843.87. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 36,847 shares of company stock worth $3,033,340 over the last three months. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 27th. Stockholders of record on Friday, September 13th were issued a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 3.61%. The ex-dividend date of this dividend was Friday, September 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 855.56%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.